Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 2 entries
    • Eligibility criteria expanded, about 4 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 6 of 6 sites
    v3
  3. Site details revised at 2 of 6 sitesv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.
Trial Details
NCT Number NCT07213583
Lead Sponsor Neurimmune AG
Collaborators: Alexion Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Amyloid Transthyretin Cardiomyopathy
Related terms Amyloidosis
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov